Vaccibody completes enrolment of patients for phase I study
(26.05.16)

| News

Vaccibody AS has announced the successful enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16). Read more.

Sarsia Seed